Levonorgestrel-releasing intrauterine system versus conventional medical therapy for heavy menstrual bleeding in the Asia-Pacific region

Int J Gynaecol Obstet. 2013 Apr;121(1):24-30. doi: 10.1016/j.ijgo.2012.10.028. Epub 2013 Jan 20.

Abstract

Objective: To compare clinical outcomes, including cumulative continuation rate (CCR), in the treatment of idiopathic heavy menstrual bleeding (HMB) with the levonorgestrel-releasing intrauterine system (LNG-IUS) and with conventional medical therapies (CMTs), including combined oral contraceptives, oral progestins, and antifibrinolytics, either alone or in combination, in the Asia-Pacific region.

Methods: In a prospective observational cohort study conducted between September 2008 and December 2010, 647 women (LNG-IUS, n=483; CMTs, n=164), aged 18-45 years and diagnosed with HMB, were recruited from 8 countries and followed for up to 1 year. The primary outcome was the CCR at 12 months. Secondary outcomes included bleeding pattern, an assessment of treatment efficacy by the treating physician, and safety.

Results: The CCR at 12 months was significantly higher for LNG-IUS than for CMTs (87.6% vs 56.3% P<0.05). Compared with CMTs, LNG-IUS offered a better reduction in both subjectively assessed menstrual blood loss and the number of bleeding days, and had better efficacy for HMB, as determined by the physician's final evaluation.

Conclusion: The present study provides information on the real-life patterns of treatment of HMB in the Asia-Pacific region. The efficacy of CMTs was inferior compared with LNG-IUS in the clinical outcomes measured. ClinicalTrials.gov:NCT00864136.

Publication types

  • Comparative Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antifibrinolytic Agents / therapeutic use
  • Asia
  • Cohort Studies
  • Contraceptive Agents, Female / administration & dosage
  • Contraceptive Agents, Female / therapeutic use*
  • Contraceptives, Oral, Combined / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Intrauterine Devices, Medicated*
  • Levonorgestrel / administration & dosage
  • Levonorgestrel / therapeutic use*
  • Menorrhagia / drug therapy*
  • Middle Aged
  • Progestins / therapeutic use
  • Prospective Studies
  • Treatment Outcome
  • Young Adult

Substances

  • Antifibrinolytic Agents
  • Contraceptive Agents, Female
  • Contraceptives, Oral, Combined
  • Progestins
  • Levonorgestrel

Associated data

  • ClinicalTrials.gov/NCT00864136